153 related articles for article (PubMed ID: 33592901)
21. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.
Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH
Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638
[TBL] [Abstract][Full Text] [Related]
22. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
23. Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: A meta-analysis.
Li J; Wang X; Qu W; Wang J; Jiang SW
Clin Chim Acta; 2019 Jan; 488():215-220. PubMed ID: 30414437
[TBL] [Abstract][Full Text] [Related]
24. Human Epididymis Protein 4 (HE4) and Cancer Antigen 125 (CA125) for Prediction of Optimal Primary Surgery in Non-Mucinous Epithelial Ovarian Cancer.
Promchit K; Oranratanaphan S
Asian Pac J Cancer Prev; 2024 Jan; 25(1):281-286. PubMed ID: 38285795
[TBL] [Abstract][Full Text] [Related]
25. Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders.
Zhang Y; Qiao C; Li L; Zhao X; Li Y
Afr Health Sci; 2014 Dec; 14(4):913-8. PubMed ID: 25834501
[TBL] [Abstract][Full Text] [Related]
26. Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer.
Zhang P; Wang C; Cheng L; Zhang P; Guo L; Liu W; Zhang Z; Huang Y; Ou Q; Wen X; Tian Y
Medicine (Baltimore); 2015 Dec; 94(52):e2402. PubMed ID: 26717395
[TBL] [Abstract][Full Text] [Related]
27. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer.
Chudecka-Głaz AM; Cymbaluk-Płoska AA; Menkiszak JL; Sompolska-Rzechuła AM; Tołoczko-Grabarek AI; Rzepka-Górska IA
J Ovarian Res; 2014; 7():62. PubMed ID: 25018782
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.
Fujiwara H; Suzuki M; Takeshima N; Takizawa K; Kimura E; Nakanishi T; Yamada K; Takano H; Sasaki H; Koyama K; Ochiai K
Tumour Biol; 2015 Feb; 36(2):1045-53. PubMed ID: 25326813
[TBL] [Abstract][Full Text] [Related]
29. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.
Li F; Tie R; Chang K; Wang F; Deng S; Lu W; Yu L; Chen M
BMC Cancer; 2012 Jun; 12():258. PubMed ID: 22712526
[TBL] [Abstract][Full Text] [Related]
30. The diagnostic value of the combination of hemoglobin, CA199, CA125, and HE4 in endometriosis.
Chen T; Wei JL; Leng T; Gao F; Hou SY
J Clin Lab Anal; 2021 Sep; 35(9):e23947. PubMed ID: 34405450
[TBL] [Abstract][Full Text] [Related]
31. Serum Human Epididymis Protein-4 (HE4) - A novel Approach to Differentiate Malignant Frombenign Breast Tumors.
Sai Baba KSS; Rehman MA; Pradeep Kumar J; Fatima M; Raju GSN; Uppin SG; Mohammed N
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2509-2507. PubMed ID: 34452565
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the predictive performance of risk of malignancy indexes 1-4, HE4 and risk of malignancy algorithm in the triage of adnexal masses.
Hada A; Han LP; Chen Y; Hu QH; Yuan Y; Liu L
J Ovarian Res; 2020 Apr; 13(1):46. PubMed ID: 32334618
[TBL] [Abstract][Full Text] [Related]
33. The role of novel biomarker HE4 in endometrial cancer: a case control prospective study.
Angioli R; Plotti F; Capriglione S; Montera R; Damiani P; Ricciardi R; Aloisi A; Luvero D; Cafà EV; Dugo N; Angelucci M; Benedetti-Panici P
Tumour Biol; 2013 Feb; 34(1):571-6. PubMed ID: 23179397
[TBL] [Abstract][Full Text] [Related]
34. Measurement of HE4 six months after first-line treatment as optimal time in identifying patients at high risk of progression advanced ovarian cancer.
Kotowicz BU; Fuksiewicz M; Bidzinski M; Berezowska A; Sobiczewski P; Kowalska MM
Ginekol Pol; 2022; 93(11):910-915. PubMed ID: 36621970
[TBL] [Abstract][Full Text] [Related]
35. Serum concentrations of HE4 and Ca125 in uncomplicated pregnancies: a longitudinal study.
Uslu B; Dogan S; Özdem S; Şimşek T
J Obstet Gynaecol; 2020 Jan; 40(1):70-76. PubMed ID: 31307266
[TBL] [Abstract][Full Text] [Related]
36. Correlation analysis and clinical significance of CA125, HE4, DDI, and FDP in type II epithelial ovarian cancer.
Qiao L; Chen X; Xi X; Chen X; Zhang P; Dong H; Wu X; Chen X
Medicine (Baltimore); 2020 Dec; 99(49):e23329. PubMed ID: 33285710
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses.
Dewan R; Dewan A; Jindal M; Bhardawaj M
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1103-1108. PubMed ID: 31030480
[TBL] [Abstract][Full Text] [Related]
38. Clinical Significance of Serum HE4, CA125, CA724, and CA19-9 in Patients With Endometrial Cancer.
Bian J; Sun X; Li B; Ming L
Technol Cancer Res Treat; 2017 Aug; 16(4):435-439. PubMed ID: 27562869
[TBL] [Abstract][Full Text] [Related]
39. Serum Human Epididymis Protein 4 Combined with Carbohydrate Antigen 125 for Endometrial Carcinoma Diagnosis: A Meta-Analysis and Systematic Review.
Huang GQ; Xi YY; Zhang CJ; Jiang X
Genet Test Mol Biomarkers; 2019 Aug; 23(8):580-588. PubMed ID: 31373853
[No Abstract] [Full Text] [Related]
40. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.
Zhang L; Chen Y; Wang K
Curr Probl Cancer; 2019 Apr; 43(2):135-144. PubMed ID: 30017407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
